Clinical Trial Update: A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating FE 999302 as add-on to Follitropin Delta (REKOVELLE) for women undergoing controlled ovarian stimulation has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Controlled Ovarian Stimulation

Drugs mentioned

• FE 999302
• Follitropin Delta (REKOVELLE) (follitropin delta)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Controlled Ovarian Stimulation | Phase 2 | Status: COMPLETED